Search results for "Coagulation Disorders"

showing 2 items of 32 documents

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

2015

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community, Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations…

0301 basic medicineriesgohumanosUltrafiltrationBacteremiaBlood DonorsHepacivirus030204 cardiovascular system & hematologyParasitemia/dk/atira/pure/subjectarea/asjc/2700/27200302 clinical medicineBlood plasmaScreening methodMedicinePathogenChromatographyultrafiltraciónfungemiaTransmission (medicine)Blood ScreeningbacteriemiaHematologyBlood Coagulation DisordersChromatography Ion ExchangeSettore MED/07 - Microbiologia e Microbiologia Clinicatransfusión de componentes sanguíneos/dk/atira/pure/subjectarea/asjc/2700/2730trastornos de la coagulación sanguíneaOncologyVIH-1RiskHepatitis B virusHaemophiliaBlood Component TransfusionHaemophiliaArticlepatógenos transmitidos por la sangre03 medical and health sciencesBlood-Borne PathogensHumansViremiacromatografíaBlood safety; Clotting; Haemophilia; Pathogen; TransfusionPathogenbusiness.industryDonor selectionTransfusionClottingdonantes de sangrevirus de la hepatitis Bmedicine.diseaseResidual risk030104 developmental biologyImmunologyHIV-1businessBlood safetyBlood Reviews
researchProduct